The latest London South East Webinar takes place on July 6. Come and hear CEO’s from Orosur Mining, Caledonia Mining, Glantus Holdings and Tekcapital speak. Please register here

Less Ads, More Data, More Tools Register for FREE
Games developer tinyBuild seeks to boost £500 million market cap by becoming a media company
Games developer tinyBuild seeks to boost £500 million market cap by becoming a media companyView Video
Samarkand Group update the market at the London South East Aquis Special webinar
Samarkand Group update the market at the London South East Aquis Special webinarView Video

Latest Share Chat

Oxford Biomedica jumps after AstraZeneca orders more Covid-19 vaccines

Tue, 18th May 2021 11:52

(Alliance News) - Oxford Biomedica PLC on Tuesday raised its revenue and profit guidance after AstraZeneca PLC committed to buy more Covid-19 vaccines than previously agreed in the second half of 2021.

Shares in Oxford Biomedica were up 12% to 1,120.00 pence in London, the top performer in the FTSE 250 index on Tuesday. AstraZeneca was up 0.5% to 7,930.55p.

The two companies signed an 18-month supply deal in September under a three-year master supply and development agreement, in which Oxford Biomedica manufactures the vaccine developed by AstraZeneca and the University of Oxford.

Oxford Biomedica now expects cumulative revenue from AstraZeneca by the end of this year of more than GBP100 million, up from the previous guidance of more than GBP50 million.

As a result, there should be "significant growth" in operating earnings before interest, tax, depreciation and amortisation this year, the gene and cell therapy company said.

By Ivan Edwards; ivanedwards@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News

IN BRIEF: DeepMatter partners with universities on automated precision

IN BRIEF: DeepMatter partners with universities on automated precision

Today 19:14

Redx Pharma gets milestone sum from AstraZeneca for therapy progress

Redx Pharma gets milestone sum from AstraZeneca for therapy progress

Today 14:07

Thursday broker round-up

(Sharecast News) - Pets At Home: Liberum upgrades to buy with a target price of 510p.

Today 13:49

IP Group investee Apollo Therapeutics completes USD145 million raise

IP Group investee Apollo Therapeutics completes USD145 million raise

Today 09:48

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.